Intermittent Fasting After ST-Segment-Elevation Myocardial Infarction Improves Left Ventricular Function: The Randomized Controlled INTERFAST-MI Trial.

cardiovascular diseases dizziness intermittent fasting myocardial infarction ventricular function, left

Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
02 May 2024
Historique:
medline: 2 5 2024
pubmed: 2 5 2024
entrez: 2 5 2024
Statut: aheadofprint

Résumé

Intermittent fasting has shown positive effects on numerous cardiovascular risk factors. The INTERFAST-MI trial (Intermittent Fasting in Myocardial Infarction) has been designed to study the effects of intermittent fasting on cardiac function after STEM (ST-segment-elevation myocardial infarction) and the feasibility of future multicenter trials. The INTERFAST-MI study was a prospective, randomized, controlled, nonblinded, single-center investigator-initiated trial. From October 1, 2020, to July 15, 2022, 48 patients were randomized to the study groups intermittent fasting or regular diet and followed for 6 months with follow-up visits at 4 weeks and 3 months. In all, 22 of 24 patients in the intermittent fasting group with a mean age of 58.54±12.29 years and 20 of 24 patients in the regular diet group with a mean age of 59.60±13.11 years were included in the intention-to-treat population. The primary efficacy end point (improvement in left ventricular ejection fraction after 4 weeks) was significantly greater in the intermittent fasting group compared with the control group (mean±SD, 6.636±7.122%. versus 1.450±4.828%; Our results suggest that intermittent fasting after myocardial infarction may be safe and could improve left ventricular function after STEMI. URL: https://www.drks.de; Unique identifier: DRKS00021784.

Sections du résumé

BACKGROUND UNASSIGNED
Intermittent fasting has shown positive effects on numerous cardiovascular risk factors. The INTERFAST-MI trial (Intermittent Fasting in Myocardial Infarction) has been designed to study the effects of intermittent fasting on cardiac function after STEM (ST-segment-elevation myocardial infarction) and the feasibility of future multicenter trials.
METHODS UNASSIGNED
The INTERFAST-MI study was a prospective, randomized, controlled, nonblinded, single-center investigator-initiated trial. From October 1, 2020, to July 15, 2022, 48 patients were randomized to the study groups intermittent fasting or regular diet and followed for 6 months with follow-up visits at 4 weeks and 3 months.
RESULTS UNASSIGNED
In all, 22 of 24 patients in the intermittent fasting group with a mean age of 58.54±12.29 years and 20 of 24 patients in the regular diet group with a mean age of 59.60±13.11 years were included in the intention-to-treat population. The primary efficacy end point (improvement in left ventricular ejection fraction after 4 weeks) was significantly greater in the intermittent fasting group compared with the control group (mean±SD, 6.636±7.122%. versus 1.450±4.828%;
CONCLUSIONS UNASSIGNED
Our results suggest that intermittent fasting after myocardial infarction may be safe and could improve left ventricular function after STEMI.
REGISTRATION UNASSIGNED
URL: https://www.drks.de; Unique identifier: DRKS00021784.

Identifiants

pubmed: 38695175
doi: 10.1161/CIRCHEARTFAILURE.123.010936
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010936

Auteurs

Jochen Dutzmann (J)

Department of Internal Medicine III, University Hospital Halle (Saale), Germany. (J.D., Z.K., J.-M.D., K.K., D.G.S.).

Zoe Kefalianakis (Z)

Department of Internal Medicine III, University Hospital Halle (Saale), Germany. (J.D., Z.K., J.-M.D., K.K., D.G.S.).

Florian Kahles (F)

Department of Internal Medicine I, University Hospital Aachen, Germany (F.K.).

Jan-Marcus Daniel (JM)

Department of Internal Medicine III, University Hospital Halle (Saale), Germany. (J.D., Z.K., J.-M.D., K.K., D.G.S.).

Hubert Gufler (H)

Department of Radiology, University Hospital Halle (Saale), Germany. (H.G., W.W.).

Walter Alexander Wohlgemuth (WA)

Department of Radiology, University Hospital Halle (Saale), Germany. (H.G., W.W.).

Kai Knöpp (K)

Department of Internal Medicine III, University Hospital Halle (Saale), Germany. (J.D., Z.K., J.-M.D., K.K., D.G.S.).

Daniel G Sedding (DG)

Department of Internal Medicine III, University Hospital Halle (Saale), Germany. (J.D., Z.K., J.-M.D., K.K., D.G.S.).

Classifications MeSH